Olivier Bouché
#159,511
Most Influential Person Now
Researcher ORCID ID = 0000-0002-8284-3743
Olivier Bouché's AcademicInfluence.com Rankings
Olivier Bouchécomputer-science Degrees
Computer Science
#9040
World Rank
#9499
Historical Rank
Data Science
#216
World Rank
#221
Historical Rank
Computational Linguistics
#2120
World Rank
#2142
Historical Rank
Machine Learning
#3861
World Rank
#3907
Historical Rank
Olivier Bouchémathematics Degrees
Mathematics
#7306
World Rank
#9956
Historical Rank
Measure Theory
#2042
World Rank
#2475
Historical Rank
Download Badge
Computer Science Mathematics
Olivier Bouché's Degrees
- PhD Computer Science Université Paris Cité
- Masters Computer Science Université Paris Cité
- Bachelors Mathematics Université Paris Cité
Similar Degrees You Can Earn
Why Is Olivier Bouché Influential?
(Suggest an Edit or Addition)Olivier Bouché's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. (2011) (4954)
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (2113)
- Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. (2006) (1625)
- KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. (2008) (1528)
- Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. (2011) (1345)
- Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. (2007) (1104)
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. (2013) (980)
- Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. (1997) (938)
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. (2016) (707)
- Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. (2010) (701)
- Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (2009) (687)
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. (2008) (597)
- Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. (2008) (543)
- Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. (2006) (531)
- Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. (2013) (441)
- Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. (2013) (393)
- Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. (2012) (358)
- Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. (2014) (291)
- Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. (1999) (288)
- Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. (2012) (284)
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. (2015) (281)
- Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial (2007) (275)
- Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. (2004) (270)
- Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. (2021) (259)
- Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. (2003) (249)
- Treatment of carcinoid syndrome (2000) (218)
- Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer (2017) (196)
- Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre (2014) (189)
- Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era (2012) (180)
- Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. (2013) (180)
- Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. (2013) (177)
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). (2009) (168)
- Small Bowel Adenocarcinoma in Patients with Crohn's Disease Compared with Small Bowel Adenocarcinoma De Novo (2005) (159)
- Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. (2009) (154)
- Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. (2010) (153)
- Metastatic colorectal cancer. (2006) (151)
- Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. (2007) (151)
- Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. (2013) (150)
- Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. (2011) (145)
- Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy (2014) (145)
- Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). (2005) (144)
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. (2020) (130)
- Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. (2005) (120)
- RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study (2018) (119)
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). (2010) (116)
- A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. (2006) (115)
- Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) (2020) (113)
- Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) (2020) (113)
- Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. (2010) (107)
- What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? (2012) (106)
- Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. (2018) (103)
- Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (2017) (102)
- Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. (2015) (100)
- A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. (2016) (99)
- Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). (2018) (98)
- Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs (2012) (97)
- Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial (2004) (95)
- Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. (2004) (93)
- Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. (2016) (92)
- Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). (2008) (91)
- Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. (2008) (90)
- Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. (2013) (90)
- Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment (2017) (90)
- A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) (2005) (88)
- Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy (2014) (88)
- Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. (2018) (86)
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial (2007) (82)
- Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab (2019) (80)
- Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. (2006) (79)
- Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). (2012) (79)
- Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. (2013) (73)
- Anal carcinoma: prognostic value of endorectal ultrasound (ERUS). Results of a prospective multicenter study. (2001) (68)
- Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). (2019) (68)
- Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). (2018) (66)
- Identification of Raman spectroscopic markers for the characterization of normal and adenocarcinomatous colonic tissues. (2009) (66)
- Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial (2019) (63)
- Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). (2017) (63)
- Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. (2009) (61)
- Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. (2006) (61)
- Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). (2018) (60)
- Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. (2019) (59)
- A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy (2014) (59)
- Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). (2020) (59)
- Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer (2017) (58)
- The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. (2013) (56)
- Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. (2016) (56)
- Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). (2018) (54)
- Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance (2019) (54)
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial (2014) (53)
- [Vascular and renal effects of anti-angiogenic therapy]. (2008) (53)
- Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). (2017) (52)
- Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial (2019) (52)
- Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. (2012) (52)
- Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. (2005) (51)
- Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial (2014) (50)
- Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti‐EGFR antibodies in colorectal cancer (2010) (49)
- Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results (2017) (48)
- Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status (2017) (48)
- Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. (2014) (48)
- Infrared spectral histopathology for cancer diagnosis: a novel approach for automated pattern recognition of colon adenocarcinoma. (2014) (47)
- Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). (2019) (45)
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors (2012) (45)
- Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22). (2020) (44)
- Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. (2005) (44)
- Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone. (2015) (43)
- Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. (2011) (42)
- Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. (2006) (41)
- Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD‐NADEGE cohort study of 347 patients (2020) (41)
- Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients (2016) (41)
- Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma. (2019) (41)
- Infrared spectral imaging as a novel approach for histopathological recognition in colon cancer diagnosis (2012) (40)
- Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4) (2017) (40)
- Infrared imaging as a cancer diagnostic tool: Introducing a new concept of spectral barcodes for identifying molecular changes in colon tumors (2013) (40)
- Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial (2019) (40)
- Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) (2012) (40)
- Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration (2019) (39)
- Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. (2017) (38)
- Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial. (2016) (38)
- COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR) (2020) (38)
- Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. (1996) (38)
- Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma (2017) (36)
- Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. (2010) (36)
- Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study (2020) (35)
- Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group (2014) (35)
- Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study (2017) (35)
- Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial (2007) (34)
- Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib (2017) (34)
- Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. (2017) (34)
- Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. (2013) (33)
- A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. (2015) (33)
- Joint model for left‐censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000–05 trial (2016) (33)
- Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib (2015) (33)
- Recent insights in the therapeutic management of patients with gastric cancer. (2016) (33)
- Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study (2020) (32)
- Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. (2018) (32)
- Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): Preliminary results (2007) (31)
- The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. (2010) (31)
- Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) (2016) (31)
- Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm (2012) (30)
- Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG). (2014) (30)
- Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. (2011) (30)
- Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. (2018) (30)
- Colonic Flat Neoplasia: Frequency and Concordance Between Endoscopic Appearance and Histological Diagnosis in a French Prospective Series (2004) (29)
- Value of diffusion‐weighted and gadolinium‐enhanced MRI for the diagnosis of pelvic recurrence from colorectal cancer (2014) (28)
- Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. (2012) (27)
- LRP1 expression in colon cancer predicts clinical outcome (2018) (27)
- Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. (2017) (27)
- Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial. (2015) (27)
- Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial. (2004) (27)
- Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy (2019) (27)
- Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus (2008) (27)
- Infrared and Raman Imaging for Characterizing Complex Biological Materials: A Comparative Morpho-Spectroscopic Study of Colon Tissue (2014) (26)
- Study of 47 consecutive patients with peptic esophageal stricture compared with 3880 cases of reflux esophagitis (1992) (25)
- A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 ) (2009) (25)
- FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. (2019) (24)
- Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial). (2013) (24)
- Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). (2017) (24)
- Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer (2006) (24)
- A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer (2011) (23)
- [Recommendations for the management of GIST patients]. (2005) (22)
- Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. (2009) (22)
- Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience. (2014) (22)
- Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. (2017) (22)
- Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. (2019) (22)
- Preoperative Chemoradiotherapy (CT-RT) Improves Local Control in T3-4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial (2005) (21)
- Increased risk of colonic neoplasia in patients with sporadic duodenal adenoma. (2009) (21)
- Advances in radiological imaging of gastrointestinal tumors. (2009) (21)
- Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies. (2001) (21)
- 526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours (2020) (21)
- Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial (2020) (20)
- Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study) (2017) (20)
- Primary rectal cancer local staging. (2014) (20)
- Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial. (2006) (19)
- Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. (2012) (19)
- Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma (2020) (19)
- Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19). (2019) (19)
- Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients (2018) (19)
- Is Palliative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy Effective in Patients with Malignant Hemorrhagic Ascites? (2012) (19)
- Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. (2013) (19)
- Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial (2021) (19)
- Feasibility of systematic handgrip strength testing in digestive cancer patients treated with chemotherapy: The FIGHTDIGO study (2018) (18)
- Addition of oxaliplatin (Eloxatine®, LOHP) to the same leucovorin (LV) and 5 fluorouracil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report (1997) (18)
- Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: Pooled analysis of individual patients' data from four randomized trials. (2012) (18)
- Survey on the management of skin toxicity associated with EGFR inhibitors amongst French Physicians (2013) (18)
- Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive. (2008) (18)
- Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI). (2016) (18)
- Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients (2005) (18)
- Optical diagnosis of peritoneal metastases by infrared microscopic imaging (2009) (18)
- FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial. (2016) (18)
- Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer (2021) (17)
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. (2022) (17)
- A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study. (2013) (17)
- Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. (2005) (17)
- Time course of regorafenib-associated adverse events in the phase III CORRECT study. (2013) (17)
- Bleeding reflux esophagitis: a prospective 1-year study in a university hospital (2001) (17)
- Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma. (2016) (16)
- 46 Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803 (2003) (16)
- Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients. (2005) (16)
- [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]. (2011) (16)
- Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial (2021) (16)
- Prognostic value of baseline seric Syndecan‐1 in initially unresectable metastatic colorectal cancer patients: a simple biological score (2016) (16)
- Filiform polyposis: A benign entity? Case report and literature review. (2014) (15)
- Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. (2016) (15)
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. (2014) (15)
- Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). (2021) (14)
- Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Köhne's risk classification. (2013) (14)
- Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. (2015) (14)
- Microwave Thermoablation of Colorectal Liver Metastases Close to Large Hepatic Vessels Under Pringle Maneuver Minimizes the “Heat Sink Effect” (2020) (14)
- Time course of regorafenib-associated adverse events in the phase III CORRECT study (2013) (14)
- 473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results (2017) (14)
- BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study (2019) (14)
- A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen (2017) (14)
- FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA). (2015) (14)
- Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial. (2011) (14)
- The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers (2018) (13)
- FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802). (2015) (13)
- Experience of Gemcitabine plus Oxaliplatin Chemotherapy in Patients with Advanced Biliary Tract Carcinoma (2010) (13)
- [Protective effect of appendectomy on the development of ulcerative colitis. A case-control study]. (2001) (13)
- [Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma]. (1996) (13)
- Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). (2021) (13)
- Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). (2006) (13)
- Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG). (2017) (12)
- BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series (2016) (12)
- LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC) (2021) (12)
- An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? (2011) (12)
- Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups (2020) (12)
- Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma (2015) (12)
- Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC) (2005) (12)
- Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study (2019) (12)
- Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). (2018) (12)
- [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. (2010) (12)
- Outcome after surgical treatment of gastrointestinal stromal tumors. (2007) (11)
- Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors (2015) (11)
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
- MR imaging of pelvic extraperitoneal masses: A diagnostic approach. (2016) (11)
- Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. (2013) (11)
- Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. (2016) (11)
- A New Rapid and Sensitive LC-MS Assay for the Determination of Sorafenib in Plasma: Application to a Patient Undergoing Hemodialysis (2011) (11)
- Molecular description of ANGPT2 associated colorectal carcinoma. (2020) (11)
- Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial. (2018) (11)
- High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study (2015) (11)
- Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial (2012) (11)
- Cancer de l'estomac (2005) (10)
- PD-1 blockade in solid tumors with defects in polymerase epsilon. (2022) (10)
- Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials. (2015) (10)
- Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER) (2021) (10)
- 3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results (2007) (10)
- Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI). (2011) (10)
- Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. (2020) (10)
- Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases (2017) (9)
- Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST). (2015) (9)
- Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial (2019) (9)
- Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer (2008) (9)
- PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. (2020) (9)
- [Partial regression of Barret esophagus with high grade dysplasia and adenocarcinoma after photocoagulation and endocurietherapy under antisecretory treatment]. (1995) (9)
- Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years (2019) (9)
- 477OBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18) (2017) (9)
- KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab. (2007) (9)
- EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib (2018) (9)
- Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial (2016) (8)
- Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR) (2020) (8)
- PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)--A randomized phase II trial. (2015) (8)
- [HER2 and gastric cancer. Recommendations for clinical practice in 2011]. (2011) (8)
- Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA, SFNCM, AFSOS) (2020) (8)
- RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study. (2017) (8)
- Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors (2012) (8)
- [Fistula between Wirsung and psoas muscle]. (2005) (7)
- Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial (2018) (7)
- Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4). (2014) (7)
- [Subcutaneous seeding on the tract of percutaneous cytologic puncture with a fine needle of a hepatic metastasis from colonic adenocarcinoma]. (1994) (7)
- Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial (2021) (7)
- Outcome of erosive/ulcerative reflux oesophagitis in 181 consecutive patients 5 years after diagnosis. (1998) (7)
- PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER (2013) (7)
- Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer (CRC) (2008) (7)
- Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer (2019) (7)
- Multicenter randomized phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients (2005) (7)
- Masatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor (GIST): Results of the French Sarcoma Group phase II trial. (2009) (7)
- Capecitabine and adermatoglyphia: trouble in border! (2017) (7)
- Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis (2021) (7)
- Irinotecan for the treatment of gastric cancer (2004) (6)
- Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID) (2022) (6)
- Molecular epidemiology of GISTs: Incidence of PDGFRA and KIT exon 9 mutations in the large French population-based study molecGIST. (2009) (6)
- Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). (2020) (6)
- [Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy]. (2004) (6)
- Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). (2021) (6)
- Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians. (2011) (6)
- Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial (2022) (6)
- Puzzles in the clinical pharmacokinetics of fluorouracil. (1998) (6)
- Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. (2013) (6)
- Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. (2011) (6)
- Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts). (2011) (6)
- A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer (2008) (6)
- Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. (2017) (6)
- Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer. (2016) (6)
- [Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups]. (2020) (6)
- Sarcopenia: An important prognostic factor for males treated for a locally advanced esophageal carcinoma. (2020) (6)
- O-0021 Randomised Phase III Study of Bevacizumab + Chemotherapy Beyond Progression in Bevacizumab-Treated Patients with Metastatic Colorectal Cancer: TML Study Kras Subgroup Findings (2012) (6)
- [Pelvic MRI at 3.0 Tesla]. (2009) (6)
- Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. (2018) (6)
- [Value and limitation of ultrasound-guided percutaneous drainage in acute lithiasic cholecystitis]. (1993) (6)
- Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial (2016) (5)
- Liver angulometry: a simple method to estimate liver volume and ratios. (2013) (5)
- Bleeding reflux esophagitis: a prospective 1-year study in a university hospital. (2001) (5)
- Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update (2012) (5)
- Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study. (2021) (5)
- Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer. (2007) (5)
- Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib (2013) (5)
- ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up. (2016) (5)
- Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary study Circe 07 of the LAP 07 trial. (2013) (5)
- Efficacy and safety of perioperative chemotherapy with 5FU-cisplatine-cetuximab in gastric and gastroesophageal junction adenocarcinomas (GGOJA): A single-arm multicenter phase II trial (FFCD 0901). (2015) (5)
- Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial (2020) (5)
- [Gastrointestinal stromal tumors (GIST)<5 cm in size: review of the literature and expert propositions for clinical management]. (2010) (5)
- Clinical experience with sunitinib (SU) in patients over age 65 with metastatic gastrointestinal stromal tumors (GIST): A retrospective study from the French Sarcoma Group (FSG). (2013) (5)
- Fully laparoscopic thermo-ablation of liver malignancies with or without liver resection: tumor location is an independent local recurrence risk factor (2020) (5)
- [Postoperative imaging after colorectal surgery]. (2009) (5)
- E13Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months (2015) (5)
- Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial. (2012) (5)
- Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147) (2012) (5)
- [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]. (2015) (5)
- cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study. (2019) (5)
- Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. (2020) (5)
- [Recommendations for the management of gastro-intestinal stromal tumors]. (2006) (4)
- Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel? (2016) (4)
- O-0012 Prognostic Factors of Overall Survival (OS) in Previously Treated Advanced Gastric Cancer (AGC): Analysis of the Phase 3 Granite-1 Trial (2012) (4)
- [Targeted biotherapies in digestive oncology: management of adverse effects]. (2009) (4)
- [Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]. (2004) (4)
- Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France (2019) (4)
- [Rectal leiomyosarcoma. 4 new cases]. (1999) (4)
- LBA46PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DOVITINIB IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) REFRACTORY AND/OR INTOLERANT TO IMATINIB (IM) (2014) (4)
- Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact (2022) (4)
- Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter trial. (2020) (4)
- FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial. (2018) (4)
- Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials (2007) (4)
- Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST). (2011) (4)
- Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. (2013) (4)
- Pancreas cancer-associated polymyositis of the legs regressing after cephalic duodenopancreatectomy: case report and review of the literature. (2012) (4)
- LBA45A RANDOMIZED MULTICENTRE PHASE II STUDY OF PAZOPANIB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE IN METASTATIC GASTROINTESTINAL STROMAL TUMORS (GIST) RESISTANT TO IMATINIB AND SUNITINIB (2014) (4)
- Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial. (2016) (3)
- Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer (2007) (3)
- OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer (2018) (3)
- [Is there still a place for surgery in the treatment of communicating pseudocyst in chronic pancreatitis?]. (1993) (3)
- Laparoscopic thermal ablation of splenic metastases initial experience and present aspects. (2013) (3)
- Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2). (2016) (3)
- [Recommendations for clinical practice: management of stomach adenocarcinoma]. (2006) (3)
- PRODIGE 2 phase III trial neoadjuvant in rectal cancer: Quality of life and results at 5 years. (2016) (3)
- Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study (2021) (3)
- Incidental gastrointestinal 18F-Fluorodeoxyglucose uptake associated with lung cancer (2015) (3)
- Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial. (2012) (3)
- Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. (2006) (3)
- Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study. (2022) (3)
- [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]. (2019) (3)
- [Cronkhite-Canada syndrome: a new French case]. (1999) (3)
- Evaluation of a fully automated extended RAS-BRAF test on prospectively collected plasma samples from patients with metastatic colorectal cancer. (2017) (3)
- 398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial (2020) (3)
- Dynapenia in digestive cancer outpatients: association with markers of functional and nutritional status (the FIGHTDIGO study) (2021) (3)
- Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. (2020) (3)
- Desmoid tumors located in the abdomen or associated with adenomatous polyposis: French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). (2022) (2)
- Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 - UCGI 35 - REGIRI). (2019) (2)
- Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). (2020) (2)
- Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study. (2020) (2)
- [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. (2010) (2)
- E17Cavitation of lung metastases induced by regorafenib is associated with radiological response in metastatic colorectal cancer: data from the phase III correct study (2015) (2)
- Abstract 5235: Circulating tumor DNA as a prognostic marker in colorectal cancer: Preliminary results of a prospective trial (2015) (2)
- Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma. (2017) (2)
- Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. (2015) (2)
- Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics (2016) (2)
- 6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI) (2011) (2)
- Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: A French Sarcoma Group (FSG) retrospective review. (2010) (2)
- Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival? (2022) (2)
- Limited Resection Versus Pancreaticoduodenectomy for Duodenal Gastrointestinal Stromal Tumors? Enucleation Interferes in the Debate: A European Multicenter Retrospective Cohort Study (2021) (2)
- Geriatric factors to predict toxicity and dose-intensity reduction in FFCD 2001-02 phase III study comparing a first-line chemotherapy of LV5FU2 or FOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderly patients. (2011) (2)
- Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis (2022) (2)
- The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy. (2016) (2)
- Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients (2021) (2)
- Sorafenib (S) in combination with irinotecan (I) as a treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS mutation (mt) as second line or later: Interim analysis results of multicenter phase II part trial (NEXIRI). (2010) (2)
- 506PDINTERIM ANALYSIS OF PRODIGE 9, A RANDOMIZED PHASE III TRIAL COMPARING NO TREATMENT TO BEVACIZUMAB MAINTENANCE DURING CHEMOTHERAPY-FREE INTERVALS IN METASTATIC COLORECTAL CANCER. (2014) (2)
- Automatic Identification of Paraffin Pixels on FTIR Images Acquired on FFPE Human Samples. (2021) (2)
- [Metastasis of pancreatic cancer in an old cholecystectomy scar]. (2005) (2)
- [Abscesses of the spleen. Value of echoguided percutaneous drainage apropos of 4 new cases]. (1994) (2)
- Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases (2022) (2)
- 1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management (2020) (2)
- Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy (2021) (2)
- Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study) (2019) (2)
- Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies (2022) (2)
- Abstract 2820: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management (2014) (2)
- Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Fédération de Recherche en Chirurgie (FRENCH) trial (2019) (2)
- PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC). (2018) (2)
- Preliminary results of capecitabine - oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): A phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003–03 trial) (2005) (2)
- Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers. (2016) (2)
- [Evaluation of the feasibility of a program of adapted physical activity in day hospital of digestive oncology: From the point of view of patients]. (2018) (2)
- Surrogate endpoints in neoadjuvant rectal cancer trials: Statistical evaluation using data from the FFCD 9203 trial (2008) (2)
- FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study (2022) (2)
- Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial): Final results. (2011) (2)
- ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort. (2018) (2)
- Nightmares and hallucinations with aprepitant and opium powder: a suspected drug–drug interaction (2018) (2)
- Definitive Results of the French FFCD-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplatin and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients With Locally Advanced Non Metastatic Pancreatic Cancer (2007) (2)
- Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. (2021) (2)
- [A case of chronic ischemic erosive gastropathy healed after surgical revascularization]. (1989) (2)
- Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. (2017) (2)
- Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study. (2013) (2)
- Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial. (2015) (2)
- 773TiPPRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma (2017) (2)
- [What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)]. (1999) (2)
- Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study) (2017) (2)
- Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20 (2016) (2)
- Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59 (2022) (2)
- O-0020 Bevacizumab + Chemotherapy Beyond First Progression in Metastatic Colorectal Cancer Patients Previously Treated with Bevacizumab-Based Therapy: TML Study Subgroup Findings (2012) (2)
- Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials. (2020) (1)
- [Value of endosonography in the diagnosis of duodenal duplication in adults]. (1997) (1)
- Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed? (2022) (1)
- [Helicobacter heilmannii-associated low-grade gastric MALT lymphoma: a new case of complete remission after eradication]. (2005) (1)
- Abstract 4211: Detection and quantification of minoritary subclones of KRAS in metastatic colorectal cancers by digital microfluidics: therapeutic implications. (2013) (1)
- Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial (2022) (1)
- Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group (2014) (1)
- A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient (2021) (1)
- Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial (2019) (1)
- 1326 Folfirinage: Tolerance and efficacy of folfirinox in elderly patients with advanced pancreatic adenocarcinoma (2015) (1)
- Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastatic colorectal cancer. (2013) (1)
- [What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]. (2006) (1)
- Abstract 2632: Clinical validation of circulating DNA analysis for the detection of point mutations and of the longitudinal metastatic colorectal patient follow up for detecting emergence of resistance to targeted therapy (2016) (1)
- 2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma (2015) (1)
- Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status. (2017) (1)
- 435P Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study (2020) (1)
- [What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)]. (1999) (1)
- [Should Helicobacter pylori be eradicated in a patient with chronic gastritis?]. (1996) (1)
- [Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectal cancer]. (2006) (1)
- [News in management of colorectal cancer at JFHOD 2012 meeting]. (2012) (1)
- Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study (2022) (1)
- M1949 Are Small Bowel Adenocarcinoma (SBA) Complicating Crohn's Disease (CD) Associated With Dysplasia? (2010) (1)
- Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial (2020) (1)
- Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA). (2004) (1)
- Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials. (2021) (1)
- Quels changements dans le Thsaurus National de Cancrologie Digestive en 2005 (2006) (1)
- 476ONeoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22) (2017) (1)
- Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. (2022) (1)
- Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA). (2017) (1)
- Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients (2023) (1)
- LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial (2020) (1)
- Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial (2019) (1)
- Response to the letter “Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients”, by C. Allior (Ann. Oncol 2004; 15: 1576–1577) (2004) (1)
- PRODIGE 34 ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer—A randomized phase III trial. (2017) (1)
- Bilan initial d’extension locorégionale d’un cancer rectal☆ (2014) (1)
- Iconography : Longitudinal quality of life study in patients with metastatic gastric cancer (2008) (1)
- [Flushing revealing the recurrence of a rectal gastrointestinal stromal tumour. Efficacy of imatinib]. (2006) (1)
- Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study. (2013) (1)
- 632PEFFICACY AND SAFETY OF PERIOPERATIVE CHEMOTHERAPY WITH 5FU-CISPLATIN-CETUXIMAB IN GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAS (GGOJA): A SINGLE ARM MULTICENTRE PHASE II TRIAL (FFCD 0901). (2014) (1)
- Prognostic value of the most frequent mutations in GIST: Results of the French population-based prospective study MolecGIST. (2010) (1)
- Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials. (2016) (1)
- 1481PDEfficacy and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib (2017) (1)
- One‐year COVID‐19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross‐sectional comprehensive study (ONCOCARE‐COV) (2022) (1)
- Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer. (2022) (1)
- O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) (2012) (1)
- 429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status (2021) (1)
- [Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]. (2021) (1)
- 702 Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer (1995) (1)
- Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. (2022) (1)
- [Digestive cancers and choroid metastasis. Diagnostic circumstances and prognostic value apropos of 2 cases]. (1997) (0)
- Iconography : Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma (2008) (0)
- Clinical, Pathological, and Molecular Characteristics in Colorectal Cancer (2022) (0)
- Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT or ACT trial). (2019) (0)
- 770P A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht) (2018) (0)
- The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers (2018) (0)
- DETECTION AND QUANTIFICATION OF MINORITY KRAS SUBCLONES IN TUMORS USING DROPLET-BASED MICROFLUIDICS: CLINICAL IMPLICATION (2013) (0)
- Un cancer épidermoïde superficiel de l’œsophage (2006) (0)
- Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort (2022) (0)
- Radical surgery in the management of initially unresectable liver metastases from colorectal cancer in the era of bio-chemotherapy (2015) (0)
- Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease? (2022) (0)
- Ectopic Pregnancy Occurring Under Colorectal Cancer Treatment : A Case Report (2019) (0)
- Simplified LV5FU2-irinotecan (FOLFIRI) in the first-line therapy of well-differentiated endocrine carcinomas of the duodeno- pancreatic area: Preliminary results of the FFCD 0302 phase II trial with GTE participation (2007) (0)
- Multidisciplinary approach for Borderline pancreatic adenocarcinoma of the head of the pancreas (2020) (0)
- [Could delayed action flanreotide be used as substitute for octreotide in the treatment of dumping syndrome?]. (1997) (0)
- [Comments on emergency treatment of biliary lithiasis in patients over 75 years of age. Apropos of 157 cases]. (1997) (0)
- PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial). (2018) (0)
- Quality of life as prognostic factor of overall survival in advanced hepatocellular carcinoma: A pooled analysis based on two French clinical trials (2008) (0)
- [Stomach cancer]. (2005) (0)
- [Morphologic aspects of peptic esophagitis and endobrachyesophagus]. (1988) (0)
- 9413 POSTER Primary Localized Gastrointestinal Stromal Tumours (GIST) of the Duodenum – a French Sarcoma Group (FSG) Retrospective Review of 84 Patients (pts) (2011) (0)
- Reflux gastro-oesophagien : biopsies endoscopiques confrontees a la ph-metrie de 24 heures : etude prospective de 113 patients (1989) (0)
- Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial. (2022) (0)
- Predictive ability of tumor growth modeling for overall survival in metastatic colorectal cancer. (2015) (0)
- Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors (2015) (0)
- Prognostic Value of the Pretherapeutic EUS Staging in Rectal Cancer Treated By Radio-(Chemo)Therapy Followed By Surgery. Long Term Results of the FFCD 9203 Randomized Study (2008) (0)
- [Colorectal lesions predisposing to cancer]. (1994) (0)
- HSA-MIR31-3P Expression as a Predictor of Anti-Egfr Response in Wild-Type Kras Patients with Metastatic Colorectal Cancer (2012) (0)
- The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown (2021) (0)
- Association between prothrombin rate, alpha-fetoprotein changes and survival of patients with advanced hepatocellular carcinoma (HCC) (2008) (0)
- Final Results of a French Sarcoma Group (FSG) Retrospective Review of 110 Patients with Primary Localized Gastrointestinal Stromal Tumors (GIST) of the Duodenum (2012) (0)
- Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". (2022) (0)
- 2349 Phase 1b/2 study results for masitinib plus irinotecan in second-line treatment of esophagogastric adenocarcinoma (2015) (0)
- Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST. (2018) (0)
- GRP-072 Exposure to Antineoplastic Agents in Oncology Departments: Practise Survey and Information to the Personnel of Three Oncology Departments (2013) (0)
- The ARCAD METACER national cohort study of brain metastases in gastro-intestinal cancers. (2016) (0)
- miRNA expression as a predictor of survival in patients with metastatic colorectal cancer treated with EGFR inhibitors. (2012) (0)
- [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)]. (2005) (0)
- Malignant gastrointestinal stromal tumors treated with imatinib in France: Results in unselected patients. (2009) (0)
- Asymptomatic stenosis of a celiacomesenteric trunk (2022) (0)
- Supplementary Material for: Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4) (2017) (0)
- Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study. (2018) (0)
- Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI-AGEO). (2016) (0)
- Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI). (2023) (0)
- Reply to E.C. Smyth et al and E. Elimova et al. (2015) (0)
- Is It Useful to Reassess Patients with Rectal Endoscopic Ultrasound After Preoperative Radiotherapy for Rectal Cancer? Long Term Results in a Randomized Trial (2008) (0)
- 557PPredictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial (2017) (0)
- Development and validation of a new prognostic score of death in patients with hepatocellular carcinoma (2008) (0)
- Reply to R. Glynne-Jones et al. (2013) (0)
- Dynamic Prediction of Resectability for Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy: Application of Joint Model for Longitudinal CA-125 Levels (2022) (0)
- Pre-requisites to the prescription of chemotherapy in colorectal cancer (2009) (0)
- Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients (2018) (0)
- Inflammatory biomarkers to predict postoperative infectious complications after cytoreductive surgery and HIPEC for peritoneal carcinomatosis. (2021) (0)
- Iconography : Outcome after surgical treatment of gastrointestinal stromal tumors (2008) (0)
- [External review of integrative oncology or complementary therapies use. Based on US academic cancer center]. (2014) (0)
- Why do guidelines supersede the conference consensus?: New French recommendations for metastatic colorectal cancer management. (2019) (0)
- Eus Assessment of the Tumor Response After Concomitant Radiochemotherapy in Esophageal Cancer. Diagnostic and Prognostic Implications (2004) (0)
- Peripheral natural killer cells are a prognostic factor in advanced oesogastric adenocarcinoma and are associated with intestinal types in the randomized trial PRODIGE17-ACCORD20 (UNICANCER GI). (2016) (0)
- Real-Life Management of advanced Gastrointestinal Stromal Tumors (GIST) Treated with Imatinib in France (2012) (0)
- PCN10 MALIGNANT GASTROINTESTINAL STROMAL TUMORS TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE (2009) (0)
- [Poorly differentiated endocrine carcinoma and adenocarcinoma on Barrett's esophagus]. (2005) (0)
- Unresectable pancreatic cancer: survival and secondary resections after chemoradiotherapy followed by gemcitabine compared to gemcitabine alone (SFRO/FFCD 2000-01 phase III trial). (2007) (0)
- Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial). Results of a planned interim analysis. (2009) (0)
- Abstract 2741: Spectral histopathology of paraffinised colon tissue microarrays: a new approach by infrared spectral imaging for colon cancer diagnosis (2010) (0)
- OHP-006 Adverse Effects of Day-Hospital Cancer Treatment Monitored at Home: Creation of a Physicianñpatient Logbook (2013) (0)
- O-009Prognostic value of BRAFV600E and KRAS exon 2 mutations in microsatellite stable stage III colon cancers from patients treated with FOLFOX + /- cetuximab: A pooled analysis from PETACC8 and N0147 trials (2015) (0)
- Time to Surgery Does Not Influence Survival Outcome in Patients With Upfront Resected Pancreatic Adenocarcinoma (2021) (0)
- 508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC) (2021) (0)
- [Dumping syndrome after total esophago-gastrectomy for caustic stenosis. Efficacy of octreotide]. (1994) (0)
- Iconographies supplémentaires de l'article : Outcome after surgical treatment of gastrointestinal stromal tumors (2008) (0)
- [Small bowel adenocarcinoma revealing Crohn's disease]. (2005) (0)
- Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial (2020) (0)
- Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial. (2023) (0)
- Identification of circulating biomarkers of Crohn's disease and spondyloarthritis using Fourier transform infrared spectroscopy (2022) (0)
- 1454P PARAFIRIGAST: Paclitaxel/ramucirumab versus FOLFIRI as second line chemotherapy of metastatic gastric cancer: An AGEO multicenter comparative study with a propensity score analysis (2020) (0)
- Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients. Authors' reply (2004) (0)
- Evolution of pain in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4). (2015) (0)
- [Cutaneous adverse reactions of EGFR (epidermal growth factor receptor)-inhibitors: therapeutic algorithm of the French PROCUR group]. (2013) (0)
- Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]. (2020) (0)
- Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer (2022) (0)
- [Targeted biotherapies in digestive oncology: a new era in therapeutic management?]. (2005) (0)
- Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study (2019) (0)
- Management in oncology during COVID-19 epidemic/ Prise en charge en oncologie digestive dans le contexte du COVID-19 (2020) (0)
- Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer. (2018) (0)
- Contents Vol. 105, 2017 (2017) (0)
- Expression of the Serrated Markers Annexin A10 or Gremlin1 in Colonic Adenocarcinomas: Morphology and Prognostic Values (2020) (0)
- Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study. (2016) (0)
- [How can the prognosis of gastric cancer be improved in France?]. (2005) (0)
- Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study (2023) (0)
- Abstract CT021: PD-1 blockade in solid tumors with defects in polymerase epsilon (2022) (0)
- Prognostic score for synchronous metastatic rectal cancer: A real-world study. (2023) (0)
- Iconography : Metastatic colorectal cancer (2008) (0)
- Locoregional relapses in the accord12/0405-prodige 02 study: dosimetric study and risk factors. (2021) (0)
- Impact of Early Palliative Care on End of Life in Advanced Biliary Tract Cancer Patients (2021) (0)
- Author's reply: "A lesion suspected of being a desmoid tumor in the context of familial adenomatous polyposis should be biopsied". (2022) (0)
- Primary localized gastrointestinal stromal tumors (GIST) of the duodenum: Final results of a French Sarcoma Group (FSG) retrospective review of 110 patients (pts). (2012) (0)
- Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX) (2022) (0)
- 632P EFFICACY AND SAFETY OF PERIOPERATIVE CHEMOTHERAPY (2014) (0)
- Lésions planes colorectales: corrélations histo-endoscopiques (1999) (0)
- Iconography : Complementary and alternative medicine use by patients with inflammatory bowel disease (2008) (0)
- Optimal Cut-Points for QLQ-C30 Scales Associated With Overall Survival in Patients with Advanced Hepatocellular Carcinoma (AHCC): a Comparison of Two Methods (2012) (0)
- A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen (2017) (0)
- Malignant gastrointestinal stromal tumors treated with imatinib in France: Results in unselected patients (2009) (0)
- Masitinib in comparison to imatinib as first-line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial. (2012) (0)
- Morphological and clinical characteristics of 41 cases of flat colorectal cancers (pT1 stage) (2001) (0)
- 3527 POSTER Outcome of the non randomized patients in the FFCD 9102 trial: chemo-radiation followed by surgery compared with chemo-radiation alone in squamous cancer of the esophagus (2007) (0)
- Selective indications of surgery in esophageal gastrointestinal stromal tumors: A retrospective study of the French Sarcoma Group (FSG). (2015) (0)
- Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort. (2021) (0)
- Hypermethylated circulating DNA detection using picoliter droplet-based PCR in colorectal cancer. (2016) (0)
- Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology) (2008) (0)
- Abstract 733: Infrared spectral imaging: a new automated diagnostic tool for colon cancer. (2013) (0)
- Gastric linitis: Results of a French national survey confirming the specificity of this gastric neoplasm and the limited therapeutic options. (2010) (0)
- P.73 ARE SMALL BOWEL ADENOCARCINOMA (SBA) COMPLICATING CROHN'S DISEASE (CD) ASSOCIATEDWITH DYSPLASIA? (2010) (0)
- 211PPROGNOSTIC VALUE OF ANGIOPOIETIN-2 FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED BY CHEMOTHERAPY AND BEVACIZUMAB. (2014) (0)
- Multivariate quality of life (QoL) prognostic factor analysis in hepatocellular carcinoma (HCC) (2005) (0)
- Cannabidiol-Drug Interaction in Cancer Patients: A retrospective study in a real-life setting. (2023) (0)
- S2044 Selecting Patients for Post-Surgical Therapy in Rectal Cancer: Should We Rely On Endorectal Ultrasonography or On Histopathological Study? Results from a Randomised Multicenter Trial By the FFCD (2008) (0)
- M1018a The Efficacy of Prefixed Equimolar Nitrous Oxyde and Oxygen Mixture (N2o) for Gastroduodenal Endoscopy Tolerance: A Randomized, Double-Blind Trial, Versus Placebo (2008) (0)
- [Therapeutic strategy in the treatment of gastroesophageal reflux]. (1990) (0)
- PD-0025DISEASE PROGRESSION PATTERNS/OUTCOME BY DISEASE EXTENT FOLLOWING BEVACIZUMAB + CHEMOTHERAPY BEYOND FIRST DISEASE PROGRESSION IN PREVIOUSLY TREATED MCRC (ML18147 STUDY) (2013) (0)
- Classic or simplified LV5FU2 regimen: Multivariate analysis from a phase III study in metastatic colorectal cancer in elderly patients. (2017) (0)
- Flat lesions of the colon and rectum: endoscopic and histopathological features (1999) (0)
- Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer. (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Olivier Bouché?
Olivier Bouché is affiliated with the following schools:
